Physician profile
David Behar
NPI 1497739916
$3,620.54
in general payments reported to CMS, 2019-2025
22 companies · $1,506 in 2025
The $1,506 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,230 · 2020: $433 · 2021: $159 · 2022: $59.40 · 2023: $32.08 · 2024: $202 · 2025: $1,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,380 · Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,380.00 |
| Food and Beverage | $359.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,587.09 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $471.33 | 2019-2021 | |
| Alkermes, INC. | $242.83 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $228.82 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $190.10 | 2019-2024 | Invega Sustenna |
| Sunovion Pharmaceuticals INC. | $189.04 | 2019-2021 | |
| Allergan, INC. | $115.29 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.28 | 2019-2021 | |
| Abbvie INC. | $76.92 | 2021-2024 | Vraylar |
| Vanda Pharmaceuticals INC. | $67.24 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $62.19 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $43.91 | 2019-2020 | |
| Indivior INC. | $38.15 | 2020-2025 | Sublocade |
| Vertical Pharmaceuticals, LLC | $36.21 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $29.04 | 2023-2024 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $28.86 | 2019-2021 | |
| Tris Pharma INC | $26.96 | 2021-2022 | |
| Shire North American Group INC | $26.63 | 2019 | |
| Novo Nordisk INC | $17.76 | 2025 | |
| Corium, LLC | $16.49 | 2022 | |
| Avanir Pharmaceuticals, INC. | $14.58 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Behar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.